Preparation of the EBS Beam Commissioning

International audienceIn 2020 the ESRF storage ring will be upgraded to a Hybrid Multi Bend Achromat (HMBA) lattice. The commissioning of the new ring will require dedicated tools, either updated from the existing ones or newly developed. Most of the software and procedures were tested on the existing storage ring before its decommissioning. In particular we present experiments on first-turn steering and beam accumulation, check of magnet polarity and calibration, and injection tuning. The use of a control-system simulator proved to be crucial for the debugging of the software and the development of the new control system, as far as beam measurements and manipulations are concerned

The ESRF's Extremely Brilliant Source - a 4th Generation Light Source

International audienceAfter 20 years of operation, the ESRF has embarked upon an extremely challenging project - the Extremely Brilliant Source (ESRF - EBS) . The goal of this project is to construct a 4th generation light source storage ring inside the existing 844m long tunnel. The EBS will increase the brilliance and coherence by a factor of 100 with respect to the present ESRF storage ring. A major challenge is to keep the present ring operating 24x7 while designing and pre-constructing all the elements of the new ring. This is the first time a 4th generation light source will be constructing inside an existing tunnel. This paper concentrates on the control system aspects. The control system is 100% TANGO based. The paper will list the main challenges of the new storage ring like the Hot Swap Powersupply, the new timing system, how reliable operation was maintained while modernizing the injector control system and preparing the new storage ring control system, the new historical database, and how extensive use was made of software simulators achieve this

Operation Improvements and Emittance Reduction of the ESRF Booster

International audienceThe ESRF storage ring will be replaced by the Extremely Brilliant Source (EBS) in 2020 and the equilibrium emittance will decrease from the present 4 nmrad to 134 pmrad. The current injector system, composed by a linac and a synchrotron booster, will be used to inject into the new storage ring. To increase the injection efficiency in the new storage ring, three methods to reduce the horizontal emittance of the booster have been considered and tested. This paper presents the studies and achievements in terms of operation improvements and emittance reduction

Building S.C.A.D.A. Systems in Scientific Installations with Sardana and Taurus

International audienceSardana and Taurus form a python software suite for Supervision, Control and Data Acquisition (SCADA) optimized for scientific installations. Sardana and Taurus are open source and deliver a substantial reduction in both time and cost associated to the design, development and support of control and data acquisition systems. The project was initially developed at ALBA and later evolved to an international collaboration driven by a community of users and developers from ALBA, DESY, MAXIV and Solaris as well as other institutes and private companies. The advantages of Sardana for its adoption by other institutes are: free and open source code, comprehensive workflow for enhancement proposals, a powerful environment for building and executing macros, optimized access to the hardware and a generic Graphical User Interface (Taurus) that can be customized for every application. Sardana and Taurus are currently based on the Tango Control System framework but also capable to inter-operate to some extend with other control systems like EPICS. The software suite scales from small laboratories to large scientific institutions, allowing users to use only some parts or employ it as a whole

Effects of Standard-Dose Prophylactic, High-Dose Prophylactic, and Therapeutic Anticoagulation in Patients With Hypoxemic COVID-19 Pneumonia The ANTICOVID Randomized Clinical Trial

International audienceIMPORTANCE Given the high risk of thrombosis and anticoagulation-related bleeding in patients with hypoxemic COVID-19 pneumonia, identifying the lowest effective dose of anticoagulation therapy for these patients is imperative. OBJECTIVES To determine whether therapeutic anticoagulation (TA) or high-dose prophylactic anticoagulation (HD-PA) decreases mortality and/or disease duration compared with standard-dose prophylactic anticoagulation (SD-PA), and whether TA outperforms HD-PA; and to compare the net clinical outcomes among the 3 strategies. DESIGN, SETTINGS, AND PARTICIPANTS The ANTICOVID randomized clinical open-label trial included patients with hypoxemic COVID-19 pneumonia requiring supplemental oxygen and having no initial thrombosis on chest computer tomography with pulmonary angiogram at 23 health centers in France from April 14 to December 13, 2021. Of 339 patients randomized, 334 were included in the primary analysis-114 patients in the SD-PA group, 110 in the HD-PA, and 110 in the TA. At randomization, 90% of the patients were in the intensive care unit. Data analyses were performed from April 13, 2022, to January 3, 2023. INTERVENTIONS Patients were randomly assigned (1:1:1) to receive either SD-PA, HD-PA, or TA with low-molecular-weight or unfractionated heparin for 14 days. MAIN OUTCOMES AND MEASURES A hierarchical criterion of all-cause mortality followed by time to clinical improvement at day 28. Main secondary outcome was net clinical outcome at day 28 (composite of thrombosis, major bleeding, and all-cause death). RESULTS Among the study population of 334 individuals (mean [SD] age, 58.3 [13.0] years; 226 [67.7%] men and 108 [32.3%] women), use of HD-PA and SD-PA had similar probabilities of favorable outcome (47.3% [95%CI, 39.9% to 54.8%] vs 52.7%[95%CI, 45.2%to 60.1%]; P = .48), as did TA compared with SD-PA (50.9% [95%CI, 43.4%to 58.3%] vs 49.1% [95%CI, 41.7%to 56.6%]; P = .82) and TA compared with HD-PA (53.5%[95%CI 45.8% to 60.9%] vs 46.5% [95%CI, 39.1% to 54.2%]; P = .37). Net clinical outcome was met in 29.8% of patients receiving SD-PA (20.2%thrombosis, 2.6%bleeding, 14.0% death), 16.4% receiving HD-PA (5.5%thrombosis, 3.6%bleeding, 11.8%death), and 20.0% receiving TA (5.5% thrombosis, 3.6% bleeding, 12.7%death). Moreover, HD-PA and TA use significantly reduced thrombosis compared with SD-PA (absolute difference, -14.7 [95%CI -6.2 to -23.2] and -14.7 [95%CI -6.2 to -23.2], respectively). Use of HD-PA significantly reduced net clinical outcome compared with SD-PA (absolute difference, -13.5; 95%CI -2.6 to -24.3). CONCLUSIONS AND RELEVANCE This randomized clinical trial found that compared with SD-PA, neither HD-PAnor TAuse improved the primary hierarchical outcome of all-cause mortality or time to clinical improvement in patients with hypoxemicCOVID-19 pneumonia; however, HD-PA resulted in significantly better net clinical outcome by decreasing the risk of de novo thrombosis